The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.

Related News Articles

Headline
In a new "Safety Speaks" conversation, Jamie Orlikoff, president of Orlikoff & Associates, Inc. and AHA national adviser on governance and leadership,…
Blog
More than 16 years ago, the U.S. House of Representatives designated July as National Minority Mental Health Awareness Month. Inspired by the work of author…
Headline
Joy Lewis, AHA senior vice president of health equity strategies and executive director of AHA’s Institute for Diversity and Health Equity, shared the stage…
Headline
The Department of Health and Human Services July 23 released an amendment to a 2013 emergency declaration under the Food, Drug and Cosmetic Act that broadens…
Headline
The AHA July 19 expressed concerns to the Department of Labor about the Occupational Safety and Health Administration’s proposed emergency response rule. The…
Headline
Boston Medical Center, a private, not-for-profit, equity-led academic medical center, is the winner of AHA’s 2024 Foster G. McGaw Prize for its leadership and…